Characteristic | PsA, n = 30 | AS, n = 5 | ReA, n = 5 | UC, n = 5 | Crohn’s Disease, n = 5 | Skin Psoriasis, n = 6 |
---|---|---|---|---|---|---|
Sex, no. (%) | ||||||
Male | 18 (60) | 4 (80) | 4 (80) | 2 (40) | 3 (60) | 1 (16.7) |
Female | 12 (40) | 1 (20) | 1 (20) | 3 (60) | 2 (40) | 5 (83.3) |
Age* | 38.3 ± 8.2 | 35.2 ± 5.2 | 33.4 ± 4.2 | 37.8 ± 7.9 | 38.6 ± 5.4 | 39 ± 7.9 |
Age at onset* | 35.8 ± 8.2 | 30.4 ± 3.3 | 31.2 ± 3.3 | 36.4 ± 7.8 | 35.8 ± 6.6 | 35.2 ± 7.7 |
Disease duration* | 30.3 ± 20.1 | 57.6 ± 39.3 | 15 ± 5.2 | 16.8 ± 10.7 | 31.2 ± 16.1 | 42 ± 18.2 |
Manifestations, no. (%) | ||||||
SJC, no. (%) | 3.8 ± 1.24 | 1 ± 1.4 | 3.6 ± 2.1 | 0.0 ± 0.0 | 1 ± 1.4 | 0.0 ± 0.0 |
TJC | 3.6 ± 1.5 | 1 ± 1.4 | 3.6 ± 2.1 | 0.0 ± 0.0 | 1 ± 1.4 | 0.0 ± 0.0 |
Sacroiliitis | 27 (90) | 5 (100) | 2 (40) | 2 (40) | 0 (0) | 0 (0) |
Clinical tenosynovitis | 12 (40) | 0 (0) | 1 (20) | 0 (0) | 1 (20) | 0 (0) |
Nail dystrophy | 28 (93.3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (100) |
Spinal disease | 28 (93.3) | 5 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Slit lamp changes | 28 (93.3) | 4 (80) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Treatment, no. (%) | ||||||
Methotrexate | 30 (100) | 5 (100) | 5 (100) | 0 (0) | 0 (0) | 0 (0) |
Anti-TNF | 0 (0) | 5 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Steroids | 0 (0) | 0 (0) | 0 (0) | 5 (100) | 5 (100) | 0 (0) |
Sulfasalazine | 2 (6.7) | 0 (0) | 1 (20) | 0 (0) | 0 (0) | 0 (0) |
Mesalamine | 0 (0) | 0 (0) | 0 (0) | 5 (100) | 5 (100) | 0 (0) |
Azathioprine | 0 (0) | 0 (0) | 0 (0) | 5 (100) | 5 (100) | 0 (0) |
Topical treatment | 30 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 6 (100) |
SJC: Swollen joint count; TJC: tender joint count; PsA: psoriatic arthritis; AS: ankylosing spondylitis; ReA: reactive arthritis; UC: ulcerative colitis.
↵* Mean ± SD.